Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.
But it is still unclear how much of a threat Onpattro will be to Pfizer’s Vyndaqel.
A win in Apollo-B should open up the multi-billion cardiomyopathy market, but questions remain.
Few sizeable transactions have emerged so far this year, with small licensing deals looking like the norm.
With readout of Apollo-B approaching, can Onpattro succeed where Bridgebio’s acoramidis failed?
The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.